Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis

High rate of recurrence impaired the prognosis of hepatocellular carcinoma (HCC) after surgery. We aimed to explore the safety and efficacy of neoadjuvant drug-eluting bead transarterial chemoembolization (D-TACE) and tislelizumab therapy for resectable or borderline resectable HCC. 41 HCC patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of surgical oncology 2023-12, Vol.49 (12), p.107106-107106, Article 107106
Hauptverfasser:	Zhao, Jianping, Wang, Jingjing, Lu, Yuanxiang, Wu, Yang, Kuang, Dong, Wang, Ying, Luo, Hongchang, Xu, Anhui, Zhang, Wanguang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Carcinoma, Hepatocellular - surgery Chemoembolization, Therapeutic - methods Drug-eluting bead transarterial chemoembolization Hepatocellular carcinoma Humans Liver Neoplasms - surgery Neoadjuvant Therapy Prognosis Propensity Score Retrospective Studies Tislelizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!